PLK1 and acute myeloid leukemia: Its inhibition through volasertib (BI6727) has been studied in AML, where it was discovered that in addition to inhibiting PLK1, this compound also inhibited BRD4, which was an advantage given that previous studies have shown that PLK1 inhibition synergized the effect of BRD4 inhibitors on AML.134, 136